RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS Russian patent published in 2022 - IPC C12N7/01 A61K39/145 

FIELD: biotechnology; immunology; virology; genetics; molecular biology and medical virology.

SUBSTANCE: present invention relates to the field of biotechnology, immunology, virology, genetics, molecular biology and medical virology. Described is a recombinant influenza virus-based virus for induction of specific immunity to influenza virus and SARS-CoV-2 coronavirus and/or prevention of diseases caused by influenza virus and SARS-CoV-2 coronavirus. The combined vaccine strain ZhIV/H7+RBD₁₉₄ is a reassortant obtained by reverse genetics, the genome formula 6:2 of which meets the requirements for live attenuated influenza vaccine strains: genes encoding surface proteins hemagglutinin (HA) and neuraminidase (NA) belong to the influenza virus, and the genes encoding internal and nonstructural proteins (PB2, PB1, PA, NP, M, NS) belong to the attenuation donor A/Leningrad/134/17/57 (H2N2). At the same time, the gene encoding the HA surface protein is modified: after the signal peptide, a fragment of the SARS-CoV-2 coronavirus is inserted into the gene. The combined vaccine strain ZhIV/H7+RBD₁₉₄ actively reproduces in developing chicken embryos at an optimum temperature of 33°C, is characterized by temperature sensitivity, cold adaptation, the ability to actively replicate in MDCK cell culture, and is harmless to laboratory animals.

EFFECT: invention makes it possible to obtain a virus with high genetic stability and immunogenicity against both influenza virus and coronavirus; invention has protective efficacy in challenge studies in case of infection with influenza, as well as with coronavirus.

3 cl, 12 dwg, 3 tbl, 6 ex